Professor Joanne Webster – the Royal Veterinary College’s Chair of Parasitic Diseases – has been announced as the new Director of the London Centre for Neglected Tropical Disease Research (LCNTDR).

LCNTDR is an innovative research centre which brings together leading global experts to aid the design, implementation and evaluation of neglected tropical disease prevention, control and elimination programmes. The centre tackles diseases which affect the lives of more than 1.7 billion of the poorest people across the world.

Professor Webster will take on this new Directorship role in addition to her work at the RVC. The appointment will also strengthen the RVC’s links with the LCNTDR, of which it is a founding partner. Importantly, it will further expand both organisations’ focus on International One Health, which recognises the relationship between health and disease at the human, animal and environment interfaces.

Outlook Therapeutics has announced the appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access.
Alicia has held commercial leadership positions across the full product life cycle and exceeded goals for 14 launches across 70-plus global markets, with experience in retina, ophthalmology and leadership for launching two wet AMD/DME therapies. Alicia’s most recent product launch in ophthalmology was for Roche Genentech’s Port-Delivery System of ranibizumab, Susvimo, while she was on the team that launched and built the life cycle plan for Lucentis.

Resonant Group has appointed Mark Corbett to the newly created role of Chief Innovation Officer. Mark brings nearly 30 years' industry experience to the role, the latter half within the specialist service area of early or expanded access.

Indeed, in this area he was involved in the development of Idis, before becoming an integral member of the team that established Clinigen Group and, most recently, in the creation of Inceptua Group’s Medicines Access service offering. His prior experience spans several years pharma side at Servier Laboratories across a variety of roles.

The ABPI has appointed a new Director of the Prescription Medicines Code of Practice Authority (PMCPA).

Alex Fell, the Vice President, Head of Risk International at Amicus Therapeutics will take over the role from 06 June 2022. A member of the ABPI, Amicus is a global biotechnology company focused on delivering new medicines for people living with rare metabolic diseases.

Before joining Amicus Therapeutics, Alex spent 13 years with GSK in ethics and compliance leadership roles in the UK, USA and Singapore. His positions included Head of Ethics and Compliance for the Europe Pharmaceuticals Business, Vice President, Global Ethics and Compliance, Head of Strategy, Planning and Operations and Director in internal audit.

Alex will replace Heather Simmonds. Heather joined the ABPI in 1984, started working on the Code in 1989, and since the PMCPA was established in 1993. Heather has been the Director of the PMCPA since 1997.

Amylyx Pharmaceuticals has appointed Gina M Mazzariello as Chief Legal Officer and General Counsel, where she will oversee all legal and compliance matters for the Company. Gina brings more than 20 years of corporate and commercial legal experience in the healthcare industry and will bring a deep knowledge of industry standards related to the investigation, approval, sales and marketing of pharmaceutical products.

Prior to joining Amylyx, Gina was with Boehringer Ingelheim USA for almost 15 years in roles of increasing responsibility. She most recently served as Vice President, Human Pharma Business Law, where she was responsible for operational legal support of the US. human pharmaceuticals business. As head business lawyer, she led a team of lawyers and paraprofessionals providing legal counsel, strategy and cross-functional support across research, development, medicine, market access and commercial teams.

OVID Health, a leading independent health communications agency, has announced the appointment of ex-Sanofi lead Cameron Miller as an Associate Director. Cameron will play a senior role in advising the agency’s growing patient advocacy and public affairs client roster.

Prior to joining OVID, Cameron led Sanofi UK’s public affairs and advocacy work in rare diseases and vaccines. Before Sanofi, Cameron was The Brain Tumour Charity’s Head of Policy and Public Affairs where he helped to secure Ministerial commitment to improve outcomes for brain tumour patients. He was also a regional organiser for Ed Miliband and has worked at The Patients Association.

Sanofi’s Board of Directors has proposed the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent directors.

At a recent meeting, Sanofi’s Board of Directors proposed, on the occasion of its next General Shareholder Meeting to be held on 3 May 2022, the renewal of the mandates of Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp and the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent directors.

Carole Ferrand is currently Chief Financial Officer of the Capgemini Group and Director of Fnac Darty. She began her career in 1992 at PricewaterhouseCoopers where she worked as an auditor and then a financial advisor. After ten years at Sony France, she was appointed Chief Financial Officer of Europacorp Group in 2011. In 2013, she became Finance Director of the Artémis Group. She also served on the Board of Directors of Capgemini for two years before being appointed Group CFO.

Emile Voest is currently director of Cancer Core Europe and was Executive Medical Director of the Netherlands Cancer Institute until 2021. He has been Professor of Medical Oncology at the University of Utrecht since 1999 and leads several precision medicine initiatives in oncology. He is co-founder and non-executive board member of the Hartwig Medical Foundation.

Over the last few years, he has also fulfilled several leadership roles in medical societies such as ESMO and ASCO.

Antoine Yver took over in 2021 as Chief Medical Officer of Centessa Pharmaceuticals. He began his career at Rhône Poulenc Rorer. In 1999, he joined the Aventis Group as Senior Director, Oncology Global Clinical Development. He was appointed Senior Director of Oncology at Johnson & Johnson in 2005 and later became Executive Director of Oncology at Schering-Plough. From 2009 to 2016, he led global oncology development at AstraZeneca before joining Daiichi Sankyo.